Understanding and overcoming drug resistance to EGFR-inhibitors for lung cancer

2015 Fiscal Year Final Research Report

• Project/Area Number: 25293302
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Okayama University
• Principal Investigator: Toyooka Shinichi 岡山大学, 医歯(薬)学総合研究科, 教授 (30397880)
• Co-Investigator(Kenkyū-buntansha): SOH Junichi 岡山大学, 病院, 講師 (90559890) ; MATSUDA Fumihiko 京都大学, 大学院医学研究科, 教授 (50212220) ; YAMAMOTO Hiromasa 岡山大学, 病院, 助教 (40467733) ; TSUKUDA Kazunori 岡山大学, 病院, 講師 (20346430) ; ASANO Hiroaki 岡山大学, 病院, 助教 (70534775) ; MIYOSHI Shinichiro 岡山大学, 大学院医歯薬学総合研究科, 教授 (00190827) ; SHIEN Kazuhiko 岡山大学, 大学院医歯薬学総合研究科, 助教 (30708079)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 原発性肺癌 / 薬剤耐性 / 癌幹細胞 / 上皮成長因子受容体チロシンキナーゼ阻害剤

Outline of Final Research Achievements

In this study, we aimed to understand and overcome drug resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI) for lung cancer. We established EGFR-TKI resistant lung cancer cell lines, and specified several resistant mechanisms to EGFR-TKI by using these cell lines. Among them, we identified that acquiring of stem-cell like characteristics led to EGFR-TKI resistance, and several novel drugs were still effective to EGFR-TKI resistant cells. It is important to select an appropriate drug to treat acquired EGFR-TKI resistant cells according to each resistant mechanism.

Free Research Field

呼吸器外科学